The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

Leuk Lymphoma. 2014 Nov;55(11):2665-8. doi: 10.3109/10428194.2014.900765. Epub 2014 Apr 22.

Authors

Annamaria Brioli¹, Lorenzo Melchor, Ian Titley, Gowri Vijayaraghavan, Claire Stephens, Athanasia Zeisig, Charlotte Pawlyn, Michele Cavo, Ricardo Morilla, Faith E Davies, Gareth J Morgan

Affiliation

¹ Myeloma Research Centre, Division of Molecular Pathology, The Institute of Cancer Research , London , UK.

PMID: 24660850
DOI: 10.3109/10428194.2014.900765

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Bone Marrow / drug effects*
Bone Marrow / pathology
Flow Cytometry
Hematopoiesis / drug effects
Humans
Immunologic Factors / adverse effects
Immunologic Factors / therapeutic use
Lenalidomide
Middle Aged
Multiple Myeloma / blood
Multiple Myeloma / drug therapy*
Survival Analysis
Thalidomide / adverse effects
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use
Time Factors
Treatment Outcome
Young Adult

Substances

Immunologic Factors
Thalidomide
Lenalidomide